ACSS3

Across TCGA pan-cancer cohorts, ACSS3 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ACSS3 data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ACSS3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ACSS3 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

LUAD, PAAD, and KIRP are the cancer types where ACSS3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.344	0.722	<.001	38	view →
PAAD	OS	Median	All	0.140	0.590	<.001	24	view →
KIRP	OS	Median	All	0.270	0.903	.009	9	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
HNSC	OS	Median	II,III,IV	0.267	0.714	.048	3	view →
BLCA	DFS	Median	III,IV	0.762	0.427	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ACSS3–LUAD (OS)

Open the LUAD breakdown →